Literature DB >> 10513643

HAART in HIV-infected patients: restoration of antigen-specific CD4 T-cell responses in vitro is correlated with CD4 memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decrease in viraemia.

T Wendland1, H Furrer, P L Vernazza, K Frutig, A Christen, L Matter, R Malinverni, W J Pichler.   

Abstract

OBJECTIVE: To analyse prospectively the effect of highly active antiretroviral treatment (HAART) on CD4 T-cell responses in vitro and in vivo in HIV-infected patients.
DESIGN: Prospective study with 49 protease inhibitor-naive adult patients. Data were collected at baseline and after 3 and 6 months of HAART.
METHODS: In vitro CD4 T-cell reactivity was analysed by stimulation of peripheral blood mononuclear cells with several antigens. In vivo CD4 T-cell reactivity (delayed type hypersensitivity) was assessed by Multitest Merieux. Both measurements were correlated to CD4 (memory) T-cell count and HIV-1 viraemia.
RESULTS: Restoration of specific CD4 T-cell proliferation was observed in most patients. The in vitro T-cell response was restored more frequently against antigens to which the immune system is constantly exposed (Candida albicans, Mycobacterium tuberculosis, M. avium) as compared with a low-exposure antigen (tetanus toxoid). Overall, delayed type hypersensitivity detection rate increased under HAART. Multivariate analysis showed improvement of antigen-specific T-cell proliferation to be significantly associated with an increase in memory CD4 T-cells, whereas improvement of the delayed type hypersensitivity response was associated with a decrease in plasma HIV-1 RNA.
CONCLUSIONS: HAART for 6 months restored antigen-specific CD4 T-cell response to several antigens. In vitro immune reconstitution was closely correlated with an increase in memory CD4 cells. Restoration of delayed type hypersensitivity was associated with suppression of viraemia. It appears that in addition to expansion of memory CD4 cells, suppression of viraemia following HAART may allow an improved inflammatory reaction, thus providing even stronger immune reconstitution.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10513643     DOI: 10.1097/00002030-199910010-00007

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  32 in total

1.  Cytotoxic HIV-1 p55gag-specific CD4+ T cells produce HIV-inhibitory cytokines and chemokines.

Authors:  Barbara Lotti; Thomas Wendland; Hansjakob Furrer; Nikhil Yawalkar; Salome von Greyerz; Karin Schnyder; Marlène Brandes; Pietro Vernazza; Ralf Wagner; Thi Nguyen; Eric Rosenberg; Werner J Pichler; Christian Brander
Journal:  J Clin Immunol       Date:  2002-09       Impact factor: 8.317

2.  Normalization of FoxP3(+) regulatory T cells in response to effective antiretroviral therapy.

Authors:  Martin Montes; Cesar Sanchez; Dorothy E Lewis; Edward A Graviss; Carlos Seas; Eduardo Gotuzzo; A Clinton White
Journal:  J Infect Dis       Date:  2010-12-21       Impact factor: 5.226

3.  Th1/Th2 cytokine profile in patients coinfected with HIV and Leishmania in Brazil.

Authors:  Maria Zilma Andrade Rodrigues; Maria Fernanda Rios Grassi; Sanjay Mehta; Xing-Quan Zhang; Luana Leandro Gois; Robert T Schooley; Roberto Badaro
Journal:  Clin Vaccine Immunol       Date:  2011-08-10

4.  Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it?

Authors:  S D Lawn; A D Harries; B G Williams; R E Chaisson; E Losina; K M De Cock; R Wood
Journal:  Int J Tuberc Lung Dis       Date:  2011-05       Impact factor: 2.373

5.  HIV-1 and the immune response to TB.

Authors:  Naomi F Walker; Graeme Meintjes; Robert J Wilkinson
Journal:  Future Virol       Date:  2013-01       Impact factor: 1.831

6.  Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif.

Authors:  M A Altfeld; B Livingston; N Reshamwala; P T Nguyen; M M Addo; A Shea; M Newman; J Fikes; J Sidney; P Wentworth; R Chesnut; R L Eldridge; E S Rosenberg; G K Robbins; C Brander; P E Sax; S Boswell; T Flynn; S Buchbinder; P J Goulder; B D Walker; A Sette; S A Kalams
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

7.  Persistence of genital tract T cell responses in HIV-infected women on highly active antiretroviral therapy.

Authors:  Nonhlanhla N Mkhize; Pamela P Gumbi; Lenine J Liebenberg; Yuan Ren; Peter Smith; Lynette Denny; Jo-Ann S Passmore
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

8.  Changing concepts of "latent tuberculosis infection" in patients living with HIV infection.

Authors:  Stephen D Lawn; Robin Wood; Robert J Wilkinson
Journal:  Clin Dev Immunol       Date:  2010-09-26

9.  Interleukin-15 production by monocyte-derived dendritic cells and T cell proliferation in HIV-infected patients with discordant response to highly active antiretroviral therapy.

Authors:  G d'Ettorre; G Forcina; M Andreotti; L Sarmati; L Palmisano; M Andreoni; S Vella; C M Mastroianni; V Vullo
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

10.  Polychromatic immunophenotypic characterization of T cell profiles among HIV-infected patients experiencing immune reconstitution inflammatory syndrome (IRIS).

Authors:  David M Murdoch; Melinda S Suchard; Willem D F Venter; Patrick Mhlangu; Janet S Ottinger; Charles Feldman; Annelies Van Rie; Deborah K Glencross; Wendy S Stevens; Kent J Weinhold
Journal:  AIDS Res Ther       Date:  2009-07-16       Impact factor: 2.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.